Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;78(5):e168-e169.
doi: 10.1016/j.jhep.2023.01.022. Epub 2023 Feb 1.

Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues"

Veeral Ajmera  1 , Rohit Loomba  2
Affiliations
Comment

Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues"

Veeral Ajmera et al. J Hepatol. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.

Please refer to the accompanying ICMJE disclosure forms for further details.

Comment on

References

    1. Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 2022;S0168–8278(22)03302–5. - PMC - PubMed
    1. Binet Q, Hermans MP, Lanthier N. Screening for NAFLD and its severity in type 2 diabetic patients: value of magnetic resonance imaging and outstanding issues. J Hepatol 2022. - PubMed
    1. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 2022;18:55–66. - PMC - PubMed
    1. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793–801. - PubMed
    1. Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 2021:101167. - PMC - PubMed

MeSH terms